Codiak Biosciences Competitors and Similar CompaniesClear all
Codiak Biosciences's competitors and similar companies include Nimbus Therapeutics, Takeda, AstraZeneca and Evox Therapeutics.
 Codiak Biosciences Codiak Biosciences is a biopharmaceutical company focused on the development of exosome-based therapeutics. |  Nimbus Therapeutics Nimbus Therapeutics is a biotechnology company which operates an application of computational chemistry to design treatments for substantial and underserved human diseases. |  Takeda Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products. |  AstraZeneca AstraZeneca is a biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines. |  Evox Therapeutics Evox Therapeutics is a biotechnology company developing exosome-based gene editing therapies. | |
Founding Date | Founding Date 2015 | Founding Date 2009 | Founding Date 1781 | Founding Date 1999 | Founding Date 2016 |
Type | Type Public | Type Private | Type Public | Type Public | Type Subsidiary |
Tags | |||||
Locations | Locations Cambridge, US HQ | Locations Cambridge, US HQ | Locations Cambridge, GB HQ Alger, DZ Buenos Aires, AR Macquarie Park, AU Macquarie Park, AU North Ryde, AU Wien, AT see more | Locations Oxford, GB HQ | |
Employees | Employees 992% decrease | Employees 1091% increase | Employees 47,4554% decrease | Employees 94,300 | Employees 452% decrease |
Valuation ($) | Valuation ($) 2.8 m | Valuation ($) N/A | Valuation ($) 43.7 b | Valuation ($) 2.7 b | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $22.9m (FY, 2021) | Revenue (est.) N/A | Revenue (est.) ¥4.5t (FY, 2026) | Revenue (est.) $58.7b (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods ¥850.5b (FY, 2026) | Cost of goods $4.9b (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit ¥3.7t (FY, 2026) | Gross profit $54.2b (FY, 2025) | Gross profit N/A |
Net income | Net income ($37.2m) (FY, 2021) | Net income N/A | Net income ¥192b (FY, 2026) | Net income $10.2b (FY, 2025) | Net income N/A |
Operating ⚠ | |||||
Phase II Trials Products | Phase II Trials Products 2 (Q2, 2020) | Phase II Trials Products N/A | Phase II Trials Products 10 (May, 2025) | Phase II Trials Products N/A | Phase II Trials Products N/A |
Funding | |||||
Total funding raised | Total funding raised $ 168.5m | Total funding raised $ 242m | Total funding raised $ 57.8m | Total funding raised $ 1b | Total funding raised $ 158.6m |
For sources of this data, please see the company profile
View Company Profiles
Nimbus Therapeutics
HQ
Cambridge, US
Employees
109↑ 1% increase
Nimbus Therapeutics is a biotechnology company which operates an application of computational chemistry to design treatments for substantial and underserved human diseases.
View companyTakeda
HQ
Tokyo, JP
Employees
47,455↓ 4% decrease
Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products.
View companyAstraZeneca
HQ
Cambridge, GB
Employees
94,300
AstraZeneca is a biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines.
View companyEvox Therapeutics
HQ
Oxford, GB
Evox Therapeutics is a biotechnology company developing exosome-based gene editing therapies.
View company